Insider Trading Alert - NATI, ARE, PVH, FTK And THC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 26, 2013, 83 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $101.20 to $90,570,406.95.

Highlighted Stocks Traded by Insiders:

National Instruments Corporation (NATI) - FREE Research Report

Kodosky Jeffrey L who is Director at National Instruments Corporation sold 4,000 shares at $31.13 on Dec. 26, 2013. Following this transaction, the Director owned 977,180 shares meaning that the stake was reduced by 0.41% with the 4,000-share transaction.

The shares most recently traded at $31.42, up $0.29, or 0.94% since the insider transaction. Historical insider transactions for National Instruments Corporation go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 43,271
  • 24-Week # shares sold: 91,271

The average volume for National Instruments Corporation has been 394,300 shares per day over the past 30 days. National Instruments Corporation has a market cap of $3.9 billion and is part of the technology sector and computer software & services industry. Shares are up 21.39% year-to-date as of the close of trading on Thursday.

National Instruments Corporation designs, manufactures, and sells tools to engineers and scientists worldwide. It offers LabVIEW, a system design software product for measurement and control; and LabVIEW Real-Time and LabVIEW FPGA that are strategic modular software add-ons. The stock currently has a dividend yield of 1.79%. The company has a P/E ratio of 57.0. Currently there is 1 analyst that rates National Instruments Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NATI - FREE

TheStreet Quant Ratings rates National Instruments Corporation as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full National Instruments Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexandria Real Estate Equities (ARE) - FREE Research Report

Richardson James H who is Director at Alexandria Real Estate Equities sold 2,500 shares at $64.45 on Dec. 26, 2013. Following this transaction, the Director owned 117,500 shares meaning that the stake was reduced by 2.08% with the 2,500-share transaction.

The shares most recently traded at $63.39, down $1.06, or 1.67% since the insider transaction. Historical insider transactions for Alexandria Real Estate Equities go as follows:

  • 4-Week # shares sold: 7,500
  • 12-Week # shares sold: 7,500
  • 24-Week # shares sold: 26,500

The average volume for Alexandria Real Estate Equities has been 432,900 shares per day over the past 30 days. Alexandria Real Estate Equities has a market cap of $4.6 billion and is part of the financial sector and real estate industry. Shares are down 7.7% year-to-date as of the close of trading on Thursday.

Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. The stock currently has a dividend yield of 4.23%. The company has a P/E ratio of 44.3. Currently there are 4 analysts that rate Alexandria Real Estate Equities a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARE - FREE

TheStreet Quant Ratings rates Alexandria Real Estate Equities as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, impressive record of earnings per share growth and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexandria Real Estate Equities Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PVH (PVH) - FREE Research Report

Grieder Daniel who is CEO, PVH Europe at PVH sold 8,010 shares at $133.27 on Dec. 26, 2013. Following this transaction, the CEO, PVH Europe owned 11,999 shares meaning that the stake was reduced by 40.03% with the 8,010-share transaction.

The shares most recently traded at $134.26, up $0.99, or 0.74% since the insider transaction. Historical insider transactions for PVH go as follows:

  • 4-Week # shares sold: 33,120
  • 12-Week # shares sold: 33,120
  • 24-Week # shares sold: 33,120

The average volume for PVH has been 873,700 shares per day over the past 30 days. PVH has a market cap of $11.0 billion and is part of the consumer goods sector and consumer non-durables industry.

PVH Corp. operates as an apparel company in the United States and internationally. Currently there are 8 analysts that rate PVH a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PVH - FREE

TheStreet Quant Ratings rates PVH as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full PVH Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Flotek Industries (FTK) - FREE Research Report

Hardy Carla S. who is Director at Flotek Industries sold 87,500 shares at $19.83 on Dec. 26, 2013. Following this transaction, the Director owned 344,021 shares meaning that the stake was reduced by 20.28% with the 87,500-share transaction.

The shares most recently traded at $19.76, down $0.07, or 0.33% since the insider transaction. Historical insider transactions for Flotek Industries go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 28,000
  • 24-Week # shares sold: 101,600

The average volume for Flotek Industries has been 565,500 shares per day over the past 30 days. Flotek Industries has a market cap of $1.0 billion and is part of the basic materials sector and chemicals industry. Shares are up 62.3% year-to-date as of the close of trading on Thursday.

Flotek Industries, Inc. engages in the research, development, design, and supply of drilling and production related products and services in the United States and internationally. The company operates through three segments: Chemicals and Logistics, Drilling Products, and Artificial Lift. The company has a P/E ratio of 21.6. Currently there are 2 analysts that rate Flotek Industries a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FTK - FREE

TheStreet Quant Ratings rates Flotek Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Flotek Industries Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Tenet Healthcare (THC) - FREE Research Report

Glenview Capital Management, Llc who is 10% Owner at Tenet Healthcare bought 248,910 shares at $39.79 on Dec. 26, 2013. Following this transaction, the 10% Owner owned 13.8 million shares meaning that the stake was reduced by 1.84% with the 248,910-share transaction.

The shares most recently traded at $41.00, up $1.21, or 2.95% since the insider transaction. Historical insider transactions for Tenet Healthcare go as follows:

  • 4-Week # shares bought: 6,250
  • 12-Week # shares bought: 25,000
  • 12-Week # shares sold: 16,582
  • 24-Week # shares bought: 25,000
  • 24-Week # shares sold: 24,873

The average volume for Tenet Healthcare has been 2.0 million shares per day over the past 30 days. Tenet Healthcare has a market cap of $4.1 billion and is part of the health care sector and health services industry. Shares are up 25.78% year-to-date as of the close of trading on Thursday.

Tenet Healthcare Corporation, an investor-owned health care services company, owns and operates acute care hospitals, ambulatory surgery centers, diagnostic imaging centers, urgent care centers, and related health care facilities in the United States. Currently there are 8 analysts that rate Tenet Healthcare a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on THC - FREE

TheStreet Quant Ratings rates Tenet Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share and revenue growth. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Tenet Healthcare Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Foxconn Chairman Terry Gou: US and China Are Waging a Global 'Tech War'

Foxconn Chairman Terry Gou: US and China Are Waging a Global 'Tech War'

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers